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Improved Serodiagnostic Testing for Lyme Disease:
Results of a Multicenter Serologic Evaluation
The diverse clinical manifestations of Lyme
disease (1-3) have led to frequent confusion in
clinical diagnosis, a confusion compounded by
problems in the accuracy and precisionof diagnos-
tic serologic tests (4-11)and thedifficultyofisolat-
ing the causative organism (12-14), Borrelia
burgdorferi. In 1990, more than 20 commercially
prepared serologic test kits for Lyme disease were
being sold in the United States, but no nationally
standardized reference test was available. A col-
laborative evaluation of a selected sample of the
commercial test kits by the Centers for Disease
ControlandPrevention(CDC)andtheAssociation
of State and Territorial Public Health Laboratory
Directors (ASTPHLD) demonstrated poor concor-
dance of results among these test kits and among
a selected group of state health department labo-
ratories (11). Because of the lack of a rigorously
defined reference serum panel, conclusions could
not be drawn about the sensitivity and specificity
of the test kits evaluated. An unexpected finding
in this study was the low concordance in test
resultsbetweenCDCandtwoconsultingacademic
reference center laboratories. A number of other
studies also have demonstrated low concordance
of Lyme disease serologic test results obtained by
a variety of laboratories (4-10).
Asaresultofthosefindings,thestudydescribed
here was designed to fulfill the following objec-
tives: 1) to assemble a serum panel from patients
who had clinically well-defined Lyme disease
(preferably confirmed by isolation of B. burgdor-
feri); healthy controls, and persons residing in
non–endemic-disease areas whose potentially
cross-reactive specimens had yielded equivocal
ELISA results in earlier CDC tests; 2) to test this
panel in a blinded fashion by several recognized
Lyme disease reference and researchlaboratories;
and 3) to compare the accuracy and precision of
tests as a prelude to developing national recom-
mendations for standardized serologic testing for
antibodies to B. burgdorferi.
Tests were performed by five academic centers
active in Lyme disease research (the Marshfield
Clinic,Marshfield,Wisconsin;University of Medi-
cine and Dentistry of New Jersey–Robert Wood
Johnson Medical School, New Brunswick, New
Jersey; State University of New York at Stony
Brook, Stony Brook, New York; Tufts/New Eng-
land Medical Center, Boston, Massachusetts; and
the University of Connecticut Health Center,
Farmington, Connecticut) and CDC’s Division of
Vector-BorneInfectiousDiseases,NationalCenter
for Infectious Diseases, based in Ft. Collins, Colo-
rado.
Serum samples from Lyme disease case-pa-
tients were obtained from the participating aca-
demic investigators (n = 72) and from the CDC
Lyme disease reference serum collection (n = 37).
All case-patient serum samples (total = 109) were
from patients who met the CDC clinical case defi-
nition for surveillance of Lyme disease (15). The
clinical manifestations in these patients ranged
from acute erythema migrans (EM) to late
neurologicdiseaseaccompaniedbyLymearthritis.
B. burgdorferi had been cultured by the method of
Berger et al. from 14 of 34 (41%) acute-phase
specimens provided by CDC (14). Duplicate speci-
mens(n=85)wererandomlyselectedfromthe109
case-patient samples for precision analysis, mak-
ing a total of 194 case-patient samples in the
panel.
Control serum samples were provided by CDC
from unpaid healthy blood donors (n = 113) who
resided in areas where Lyme disease is not en-
demic (Cincinnati, Ohio, and Atlanta, Georgia;
travel histories were not available from these do-
nors, however. Duplicate specimens (n = 87) also
were randomly selected, resulting in 200 noncase
samples in the serum panel. Additional control
samples were obtained from persons who resided
in areas where Lyme disease was not endemic but
whose physicians submitted their serum for Lyme
disease testing to CDC through their state health
department (n = 113). These specimens from pa-
tients with suspected cases had borderline
(equivocal) seroreactivity in the whole cell soni-
cate (WCS) enzyme-linked immunoassay (ELISA)
used by CDC before 1992 and are referred to
hereafter as “WCS-suspects” (16). The addition of
duplicate specimens (n = 87) brought this group to
200 equivocally seroreactive samples.
Serumwasseparatedandfrozenbytheoriginal
collectors and shipped frozen to CDC’s facilities in
Ft. Collins, Colorado. The specimens were divided
into aliquots and coded; code labels were applied
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the specimens (n = 594). The panels were then
refrozen and shipped on dry ice for blind testing
by participating investigators.All specimens were
received frozen. To calculate test sensitivity and
specificity, only the result of the sample with the
lower random code number of each pair was used.
Each laboratory employed the testing method
that it used routinely at the time this study was
undertaken (1992). CDC used an ELISA with a
WCS antigen prepared from highly passaged
strain B31 (gift of A. Barbour, University of Texas
Health Sciences Center, San Antonio, Texas) and
an ELISA with a strain B31 flagellar antigen
(FLA)thenbeingevaluated(16,17).Theotherfive
participating investigators used ELISA tests that
employed a WCS antigen of B. burgdorferi.F o u r
used assays developed in their own laboratories,
and one used a commercially available test kit
(18-22). Three investigators also tested all speci-
mens by Western blotting using published meth-
ods (19, 20). Two of these three performed
immunoblotting for IgM and IgG antibodies sepa-
rately. One laboratory tested for IgM and IgG
together.
Each participating laboratory submitted the
raw data of its results, along with a dichotomous
interpretation of those results as either positive or
negative. By prior agreement, ELISA results that
fell into a range ordinarily reported as “equivocal”
bythatlaboratoryweretreatedasnegativeforthis
analysis. Statistical analyses undertaken at CDC
included calculations of sensitivity (true positives
correctly identified), specificity (true negatives
correctly identified), precision (frequency of ob-
taining the same result on duplicate analysis of a
specimen), and a measure of concordance (agree-
ment among investigators) of results among the
tests using the kappa statistic.
Theaccuracyandprecisionoftheserologictests
as performed in 1992 by all six laboratories is
summarized in Table 1.The test methods of inves-
tigators1,2,and3producedessentiallyequivalent
results, with moderately high sensitivity (73% to
79%) for the aggregate of all case-patient samples
tested and high specificity (98% to 99.5%). Preci-
sion was high in these three laboratories for both
blood donor samples (97% to 99%) and the WCS-
suspects samples submitted from areas where
Lyme disease is nonendemic (94% to 98%). Preci-
sionwassomewhatlowerforthecase-patientsam-
ples (82% to 91%).
The performance of the other three laborato-
ries, including CDC’s, was poor. Both CDC ELISA
tests had high sensitivity (92% to 93%), but low
specificity (71% to 82%).Precision for case-patient
specimens was fairly high (92% to 93%), but low
for both non-case-patient (77% to 79%) and WCS-
suspects groups (62% to 69%). The method of in-
vestigator 4 gave very low sensitivity (49%),
moderately high specificity (91%), poor precision
with Lyme disease case-patient specimens (79%),
butgood precision withblood donor andWCS-sus-
pects samples (93% to 94%). Investigator 5, who
used a commercial test, obtained results with low
accuracy and precision.
Concordance was high (kappa statistic 0.700)
betweentheresultsofinvestigators1,2,and3.The
CDC FLA test showed moderate concordance
(kappa 0.400)with resultsfrom investigators 1,2,
and 3. The results of investigator 4 showed mod-
erate concordance with those of investigators 1
and 2 (kappa 0.400) and low concordance (0.400)
with the other results. The results of investigator
5 had low concordance with all other results. The
CDC WCS test showed moderate concordance
with the FLA test, but low concordance with re-
sults of the ELISA tests of the other laboratories.
The three investigators withthe bestresultsall
usedWesternblottosupplementtheirELISA.Two
of these three investigators submitted their di-
chotomous test interpretation with and without
using Western blot results. The sensitivity im-
proved by 20% for one investigator and by 30% for
theotherwhenWesternblotresultswereincluded.
The improvement resulted from identifying as
Table 1.Accuracy and precision of serologic tests for Lyme
disease performed in 1992
Accuracy (%) Precision (%)
Case Non-case- WCS
Investigator Sensitivity Specificity patients patients suspectsa
C D C 9 3 7 19 37 76 9
(WCS)
C D C 9 2 8 29 27 96 2
(FLA)
1 7 3 9 9 . 5 8 99 99 8
2 7 6 9 98 29 99 7
3 7 9 9 89 19 79 4
4 4 9 9 17 99 49 3
5 4 0 7 26 37 47 7
a Specimensfrompatientswithsuspectedcasesthathadborderline(equivocal)
seroreactivity in an enzyme-linked immunosorbent assay with whole-cell soni-
cate antigen (WCS).
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specimens from which an equivocal result was
obtained by ELISA and which by study design
would have been counted as negative by ELISA
results alone. Specificities were not affected by
Western blot analysis in this group of three inves-
tigators, since the serum panel in this study did
not contain cross-reactive sera; and the negative
controls and WCS-suspects had negative results
by both ELISA and Western blot.
Test sensitivity from the three laboratories
with the best test specificity (98%) was analyzed
according to the clinical manifestations in the
case-patients (Table 2). As expected, the sensitivi-
ties of the tests were lowest in specimens from
patients with early disease, 59% to 66% for
erythema migrans and 63% to 75% for early
neurologicdisease.Sensitivitiesweremuchhigher
forsamplesofpatientswithlatedisease.Sensitivi-
ties of 89% to 95% were obtained for Lyme arthri-
tis patients and91%to 100% forpersons withlate
neurologic disease, primarily encephalopathy or
polyneuropathy.
The emergence of a disease can outstrip the
development of reliable methods for its laboratory
diagnosis. The serodiagnosis of Lyme disease has
been fraught with problems of precision and accu-
racy. This study provided an opportunity for se-
lected academic research centers and CDC to
compare the performance of their individual tests
by using a serum panel from clinically well-char-
acterized patients and controls from non–en-
demic-diseaseareas.Theclinicaldiagnosisofearly
Lyme disease was supported by the isolation of B.
burgdorferifromskinbiopsyspecimens(14),when
possible. The panel, which was coded blind had a
sufficiently large number of samples (n = 335) to
provide adequate statistical power for the com-
parison.
Laboratories that supplemented their primary
test, an ELISA, with immunoblotting achieved
greater test accuracy than those that did not. The
use of Western blot as a second test enabled the
best performing laboratories to increase test sen-
sitivity without a concomitant loss of specificity.
This increase in sensitivity occurred as a result of
identifying as true positives by Western blot a
number of those specimens from patients with
clinical cases of Lyme disease that were inter-
preted as equivocal by ELISA and would have
beenotherwiseconsideredinthisstudyasdichoto-
mously negative results. Although the investiga-
tors employing Western blot tested all panel
specimens with this method, they did so at that
time to evaluate the potential value of Western
blot in Lyme disease serologic diagnosis.
The observation that Western blotting could be
employed to resolve equivocal ELISA results gave
additional impetus for evaluating its potential
adjunctive role in Lyme disease serodiagnosis and
eventually led to the finally recommended two-
testapproach(23).ThepotentialutilityofWestern
blotting, however, pointed out the lack of stand-
ardized methods for producing blots and stand-
ardized interpretive criteria.
Performance of the CDC WCS and FLA ELISA
in this study that did not include known cross-re-
active sera suggested that the positive cut-off
value for these tests was inappropriately low,
thereby increasing sensitivity at the expense of
specificity.These results
then explained the large
number of borderline
WCS ELISA results ob-
tained by CDC when it
tested the sera of pa-
tients residing in areas
where Lyme disease
was not endemic. This
group of WCS suspects
was nearly uniformly
found to be negative on
ELISA by the three
laboratories with the
best performance (Table
1) (23).
Table 2.Test sensitivity of laboratories demonstrating a test specificity of 98%
Sensitivity, % (positive samples/total)
Clinical Manifestations Laboratory 1 Laboratory 2 Laboratory 3
Erythema migrans, all 59 (55/94) 60 (56/94) 66 (62/94)
Acute phase
a 65 (11/17) 65 (11/17) 76 (13/17)
Convalescent phase
b 57 (44/77) 58 (45/77) 64 (49/77)
Carditis 100 (2/2) 100 (2/2) 100 (2/2)
Lyme arthritis
c 89 (58/65) 95 (62/65) 92 (60/65)
Neurologic, all 85 (28/33) 88 (29/33) 91 (30/33)
Early 63 (5/8) 63 (5/8) 75 (6/8)
Late 91 (10/11) 100 (11/11) 91 (10/11)
Late and arthritis 93 (13/14) 93 (13/14) 100 (14/14)
Total 74 (143/194) 77 (149/194) 79 (154/194)
a £ 30 days from onset of erythema migrans to blood collection.
b > 30 days from onset of erythema migrans to blood collection.
c Without neurologic signs or symptoms.
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testing specimens from blood bank donors. With
these samples,specificity in the three laboratories
that used immunoblotting was very high (98% to
99.5%). The test panel did not, however, contain
specimens from patients withconditions knownto
producecross-reactingantibodies(e.g.,syphilis)or
polyclonal B-cell activation (e.g., Epstein-Barr vi-
rus infection or systemic lupus erythematosus).
Thus,reported specificities in this study are likely
higher thanthey wouldhave beenif cross-reactive
specimens were included in the evaluation. Sub-
sequent studies that included cross-reactive sera
demonstrated that Western blotting correctly
identifies many false-positive ELISA reactions
(23, 24).
This study confirmed in the reference and re-
search laboratory setting the previously docu-
mented problems with accuracy and precision of
serodiagnostic tests by using WCS antigens of B.
burgdorferi (4-11). The study confirmed that a
serious disparity existed between the test results
obtained by CDC and those obtained by academic
reference centers with the best testing perform-
ances. These results guided corrective action and
led to the adoption by CDC and ASTPHLD of a
two-testapproachtoserodiagnosis(23),whichforms
the basis for the future national standardization of
Lyme disease serologic testing methods.
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